Rare Thyroid Therapeutics International AB
- Country
- 🇸🇪Sweden
- Ownership
- Subsidiary
- Established
- 2013-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.rarethyroid.com
Clinical Trials
12
Trial Phases
3 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
MCT8 Deficiency Caregiver Study
- Conditions
- Allan-Herndon-Dudley SyndromeMonocarboxylate Transporter 8 (MCT8) Deficiency
- First Posted Date
- 2023-09-29
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Rare Thyroid Therapeutics International AB
- Target Recruit Count
- 21
- Registration Number
- NCT06060197
- Locations
- 🇬🇧
Vitaccess Ltd, Oxford, Oxfordshire, United Kingdom
Expanded Access Program for Tiratricol in Patients With Monocarboxylate Transporter 8 Deficiency
- Conditions
- Monocarboxylate Transporter 8 DeficiencyAllan-Herndon-Dudley Syndrome
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2025-09-24
- Lead Sponsor
- Rare Thyroid Therapeutics International AB
- Registration Number
- NCT05911399
- Locations
- 🇺🇸
University of Alabama at Birmingham Hospital, Birmingham, Alabama, United States
🇺🇸Valley Children's Hospital, Madera, California, United States
🇺🇸Rady Children's Hospital, San Diego, California, United States
Withdrawal of Tiratricol Treatment in Males with Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency)
- Conditions
- Allan-Herndon-Dudley SyndromeMonocarboxylate Transporter 8 Deficiency
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- Rare Thyroid Therapeutics International AB
- Target Recruit Count
- 16
- Registration Number
- NCT05579327
- Locations
- 🇺🇸
Rare Disease Research, LLC, Hillsborough, North Carolina, United States
🇺🇸SSM Health Cardinal Glennon Children's Hospital, Saint Louis, Missouri, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Triac Trial II in MCT8 Deficiency Patients
- Conditions
- Allan-Herndon-Dudley Syndrome
- Interventions
- Drug: Triac
- First Posted Date
- 2015-03-24
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Rare Thyroid Therapeutics International AB
- Target Recruit Count
- 22
- Registration Number
- NCT02396459
- Locations
- 🇺🇸
Oregon Health & Science University (OHSU) Doernbecher Childrens Hospital, Portland, Oregon, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇨🇿Charles University and Motol University Hospital; The department of peadiatrics of the 2nd faculty of medicine, Praha, Czechia